Eloxatin
Peritoneal Carcinomatosis
Daping Hospital and the Research Institute of Surgery of the Third Military Medical UniversityPhase 3Active
BB
68/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 61/ 100
- Competitive Position
- 81/ 100
Competitive context
32 Active assets in the Peritoneal Carcinomatosis cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
FLUOROURACILUM Ciusss de L'Est de l'Île de Montréal | Phase 3 | BB |
CIS-DIAMMINEDICHLOROPLATINUM II National Cancer Institute (NCI) | Phase 3 | BB |
Irinotecan Catharina Ziekenhuis Eindhoven | Phase 3 | BB |
MITOMYCIN C H. Lee Moffitt Cancer Center and Research Institute | Phase 4 | BB |
Irinotecan Catharina Ziekenhuis Eindhoven | Phase 3 | BB |
View all 42 →
Same molecule, other indications
Eloxatin is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →